Table 1 Demographic and baseline characteristics

From: Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result

  Total RVO, n=66 CRVO, n=29 HRVO, n=9 BRVO, n=28
Mean age, years (SD; range) 72 (12, 47–94) 77 (10, 53–92) 70 (11, 49–79) 67 (12, 47–94)
Gender
 Male 32 (48%) 15 4 12
 Female 34 (52%) 14 5 16
Race
 Caucasian 47 (71%) 23 5 19
 Asian 12 (18%) 4 0 8
 Black 7 (11%) 2 4 1
Presenting ocular features and history
 Other eye old RVO 6 (9%) 1 0 5
 Same eye recurrence 6 (9%) 4 0 2
 Known glaucoma 14 (21%) 8 3 3
 Newly diagnosed OHT 17 (26%) 7 4 6
 Rubeotic glaucoma 3 (5%) 3 0 0
  1. Abbreviations: BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; HRVO, hemi- retinal vein occlusion; OHT, ocular hypertension; RVO, retinal vein occlusion.